HOTH - Hoth Therapeutics completes HT-001 formulation development for upcoming cancer trial

Hoth Therapeutics (HOTH) has completed the formulation for HT-001, a treatment for cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR inhibitor therapies.HT-001 is expected to start its Phase 2a trial in pending approval of the IND submission.The finalization of the HT-001 formulation will allow the company to begin IND-enabling toxicology studies and manufacturing of clinical batches for the planned Phase 2a clinical trial, the company said.Hoth had engaged a full-service contract research organization Worldwide Clinical Trials for its upcoming Phase 2a dose ranging clinical trial of HT-001 for treatment of cutaneous toxicities associated with EGFR inhibitor therapy for cancer patients, earlier this month.

For further details see:

Hoth Therapeutics completes HT-001 formulation development for upcoming cancer trial